Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 - A randomized controlled phase III trial

Journal of Clinical Oncology

Volumn 31, Issue 11, 2013, Pages 1398-1404

  Goss, Paul E ^a   Ingle, James N ^b   Pritchard, Kathleen I ^j   Ellis, Matthew J ^c   Sledge, George W ^d   Budd, G Thomas ^f   Rabaglio, Manuela ^q   Ansari, Rafat H ^e   Johnson, David B ^g   Tozer, Richard ^k   D'Souza, David P ^l   Chalchal, Haji ^o   Spadafora, Silvana ^m   Stearns, Vered ^h   Perez, Edith A ⁱ   Liedke, Pedro E R ^a   Lang, Istvan ^r   Elliott, Catherine ⁿ   Gelmon, Karen A ^p   Chapman, Judy Anne W ⁿ   Shepherd, Lois E ⁿ   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

^c MO   (United States)

^d INDIANA UNIVERSITY HEALTH   (United States)

^e Northern Indiana Cancer Research Consortium   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g Cancer Center of Kansas   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

^k JURAVINSKI CANCER CENTRE   (Canada)

^l LONDON REGIONAL CANCER PROGRAM   (Canada)

^m Algoma Regional Cancer Centre   (Canada)

ⁿ National Cancer Institute of Canada Clinical Trials Group   (Canada)

^o REGINA GENERAL HOSPITAL   (Canada)

^p BRITISH COLUMBIA CANCER AGENCY   (Canada)

^q UNIVERSITY OF BERN   (Switzerland)

^r NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; CELECOXIB; EXEMESTANE; RALOXIFENE; TRASTUZUMAB;

ACNE; ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG SAFETY; EARLY CANCER; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; OPEN STUDY; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVARIECTOMY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE; TRANSIENT ISCHEMIC ATTACK; VAGINA BLEEDING;

AGED; ANDROSTADIENES; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HISTORY, 18TH CENTURY; HOT FLASHES; HUMANS; HYPERCHOLESTEROLEMIA; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NITRILES; OSTEOPOROSIS; POSTMENOPAUSE; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84876082087     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.7805     Document Type: Article

References (29)

1. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003 (Pubitemid 37310221)
2. Breast International Group (BIG) 1-98 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005
3. Dowsett M, Jack Cuzick J, Ingle J, et al: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509-518, 2010
4. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004 (Pubitemid 38298988)
5. van de Velde CJ, Rea D, Seynaeve C, et al: Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomized phase 3 trial. Lancet 377:321-331, 2011
6. Boeddinghaus IM, Dowsett M: Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. J Steroid Biochem Mol Biol 79:85-91, 2001 (Pubitemid 34158782)
7. Lønning PE, Bajetta E, Murray R, et al: Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial. J Clin Oncol 18:2234-2244, 2000 (Pubitemid 30350215)
8. Bertelli G, Garrone O, Merlano M: Sequential use of aromatase inactivators and inhibitors in advanced breast cancer. Proc Am Soc Clin Oncol 21:34a, 2002 (abstr 238)
9. Chien AJ, Goss PE: Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 24:5305-5312, 2006 (Pubitemid 46631378)
10. Johannessen DC, Engan T, Di Salle E, et al: Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clin Cancer Res 3:1101-1108, 1997 (Pubitemid 27319756)
11. Goss PE, Qi S, Josse RG, et al: The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 34:384-392, 2004 (Pubitemid 38314903)
12. Goss PE, Hadji P, Subar M, et al: Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 9:R52, 2007
13. Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080, 2005 (Pubitemid 40365348)
14. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
15. Tu D: Minimization procedure, in Chow SC (ed): Encyclopedia of Biopharmaceutical Statistics (ed 3). New York, NY, Marcel Dekker, 2010, pp 795-798
16. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982 (Pubitemid 13149996)
17. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, version 3.0. March 31, 2003. http://ctep.cancer.gov/ protocolDevelopment/-electronic-applications/docs/ctcaev3.pdf
18. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
19. Lan KKG, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
20. Freidlin B, Korn EL: A comment on futility monitoring. Control Clin Trials 23:355-366, 2002 (Pubitemid 34874888)
21. Burstein HJ, Prestrud AA, Seidenfeld J, et al: American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796, 2010
22. Goldhirsch A, Wood WC, Coates AS, et al: Strategies for subtypes - Dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736-1747, 2011
23. National Comprehensive Cancer Network: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Breast Cancer. Version 2, 2011. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
24. National Institutes of Health: Suppression of ovarian function plus either tamoxifen or exemestane compared with tamoxifen alone in treating premenopausal women with hormone-responsive breast cancer (SOFT). ClinicalTrials.gov identifier NCT00066690. http://clinicaltrials.gov/ct2/show/ NCT00066690?term=NCT00066690&rank=1
25. Ruddy K, Mayer E, Partridge A: Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56-66, 2009
26. Ziller V, Kalder M, Albert US, et al: Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20:431-436, 2009
27. Chlebowski RT, Geller ML: Adherence to endocrine therapy for breast cancer. Oncology 71:1-9, 2006
28. Vogl SE, Altwairgi AK, Chapman J-AW, et al: Characterization of patients who received further adjuvant endocrine therapy after 5 years of aromatase inhibitors (AIs): NCIC CTG MA.27. J Clin Oncol 30, 2012 (suppl, abstr e11005)
29. Hershman DL, Cheung AM, Chapman JW, et al: Effects of adjuvant exemestane versus anastrozole on bone mineral density: Two-year results of the NCIC CTG MA.27 bone companion study. J Clin Oncol 29:49s, 2011 (suppl; abstr 518)